Article Text

Download PDFPDF
TP004/#1561  A phase 2, open-label, single-arm, prospective, multicenter study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer
  1. Lauren Dockery1,
  2. Fernanda Musa2,
  3. Cara Mathews3,
  4. Nick Spirtos4,
  5. Brian Slomovitz5,
  6. Anna Priebe6,
  7. Angela Green7,
  8. Allison Puechl8,
  9. Michael Birrer9,
  10. Thomas Herzog10,
  11. Li Ding11,
  12. Anita Schmid11,
  13. Willis Navarro11 and
  14. Kathleen Moore12
  1. 1Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City, USA
  2. 2Swedish Cancer Institute, Seattle, USA
  3. 3Women and Infants Hospital, Providence, USA
  4. 4Women’s Cancer Center of Nevada, Las Vegas, USA
  5. 5Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach, USA
  6. 6Texas Oncology, Fort Worth, USA
  7. 7Memorial Sloan Kettering Cancer Center, New York, USA
  8. 8Atrium Health Carolinas Medical Center, Charlotte, USA
  9. 9University of Arkansas for Medical Sciences, Winthrop P. Rockefeller Cancer Institute, Little Rock, USA
  10. 10University of Cincinnati Cancer Center, Cincinnati, USA
  11. 11Aadi Bioscience, Pacific Palisades, USA
  12. 12Stephenson Cancer Center, Oklahoma University Health, Oklahoma City, USA

Abstract

Introduction Dysregulation of mTOR signaling is implicated in the pathology of endometrial carcinoma (EC), particularly in endometrioid EC (EEC) in which >80% harbor PTEN or PI3K/AKT/mTOR pathway alterations. Crosstalk between mTOR and estrogen signaling pathways is associated with endocrine therapy resistance, and mTOR inhibition combined with endocrine therapy has shown benefit in patients with recurrent EC in previous phase 2 studies. nab-Sirolimus, an intravenous nanoparticle albumin-bound mTOR inhibitor (mTORi), is approved in the US for adults with advanced malignant perivascular epithelioid cell tumors. Preclinical data demonstrated improved tumor accumulation, mTOR target inhibition, and tumor growth suppression of nab-sirolimus versus other mTORis. This trial will evaluate the antitumor activity of combined mTOR and estrogen signaling pathway inhibition with nab-sirolimus and letrozole, respectively, in patients with advanced or recurrent EEC.

Methods In this phase 2, open-label, single-arm, multicenter study (NCT05997017), nab-sirolimus (100 mg/m2, intravenous, on days 1 and 8, 21-day cycle) and letrozole (2.5 mg, oral, daily) are administered to patients (~30 planned, Simon’s 2-stage design) with clinically confirmed, advanced or recurrent EEC. Eligibility criteria include age ≥18 years, ≤1 prior chemotherapy-based regimen in the advanced, metastatic, or recurrent setting (prior adjuvant chemotherapy additionally permitted), ECOG performance status 0 or 1, mTORi-naïve, and measurable disease. The primary endpoint is best overall response rate (per RECIST v1.1). Key secondary endpoints include duration of response, disease control rate, progression-free survival, overall survival, and safety. Exploratory endpoints include correlation of biomarkers with clinical outcomes.

Current Trial Status The trial is currently open for enrollment.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.